sr141716 has been researched along with Glucose Intolerance in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bukachi, FO; Makamu, BL; Mwangi, PW | 1 |
| Chen, B; Hu, N | 1 |
| Chen, W; Chen, Z; Li, S; Wang, L; Xue, N; Zheng, Z | 1 |
| Choi, JM; Jin, SM; Kim, JH; Kim, KW; Lee, S; Oh, BJ; Park, CY; Park, SW; Yang, SJ | 1 |
| Balaraman, R; Chatterjee, A; Jain, MR; Mohapatra, J; Pandya, G; Patel, PR; Sharma, M; Singh, S | 1 |
| Aouad, L; Bell-Anderson, KS; Caterson, ID; Farrell, GC; Larter, CZ; Phuyal, J; Sanz, FR; Williams, H | 1 |
| Ashton, JC; Jain, S; Mandhane, S; Nayak, P; Rajamannar, T; Soni, D | 1 |
| Chen, D; Liu, X; Shi, Y; Zhang, W | 1 |
| Majumdar, S; Padwal, R | 1 |
| Bauersachs, J; Ertl, G; Fiedler, S; Neumüller, J; Pfrang, J; Schäfer, A | 1 |
10 other study(ies) available for sr141716 and Glucose Intolerance
| Article | Year |
|---|---|
Co-administration of rimonabant prevents glucose intolerance in Sprague-Dawley rats treated chronically with lopinavir/ritonavir and zidovudine: an experimental study design.
Topics: Adult; Animals; Anti-HIV Agents; Cannabinoids; Glucose Intolerance; HIV Infections; Humans; Lopinavir; Male; Metabolic Syndrome; Rats; Rats, Sprague-Dawley; Rimonabant; Ritonavir; Zidovudine | 2023 |
Rimonabant improves metabolic parameters partially attributed to restoration of high voltage-activated Ca2+ channels in skeletal muscle in HFD-fed mice.
Topics: Animals; Blood Glucose; Body Weight; Calcium Channels; Calcium Channels, L-Type; Cannabinoid Receptor Antagonists; Diet, High-Fat; Glucose Intolerance; Insulin Resistance; Male; Mice, Inbred C57BL; Models, Animal; Muscle, Skeletal; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2017 |
Effects of CB1 receptor blockade on monosodium glutamate induced hypometabolic and hypothalamic obesity in rats.
Topics: Adipose Tissue; Animals; Animals, Newborn; Cannabinoid Receptor Antagonists; Fatty Liver; Female; Glucose Intolerance; Hyperlipidemias; Insulin Resistance; Liver; Male; Obesity; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptor, Insulin; Rimonabant; Sodium Glutamate | 2013 |
Reduced food intake is the major contributor to the protective effect of rimonabant on islet in established obesity-associated type 2 diabetes.
Topics: Adiponectin; Adiposity; Animals; Cell Proliferation; Diabetes Mellitus, Type 2; Eating; Glucose Intolerance; Insulin Resistance; Insulin-Secreting Cells; Male; Piperidines; Pyrazoles; Rats; Rats, Inbred OLETF; Receptor, Cannabinoid, CB1; Rimonabant; Rosiglitazone; Thiazolidinediones | 2013 |
Involvement of adipokines in rimonabant-mediated insulin sensitivity in ob/ob mice.
Topics: Adipokines; Adiponectin; Adipose Tissue; Adipose Tissue, White; Animals; Anti-Obesity Agents; Blood Glucose; Body Weight; Down-Regulation; Female; Gene Expression; Glucose Intolerance; Glucose Tolerance Test; Insulin; Insulin Resistance; Leptin; Mice; Mice, Knockout; Models, Animal; Nicotinamide Phosphoribosyltransferase; Obesity; Organ Size; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Retinol-Binding Proteins, Plasma; Reverse Transcriptase Polymerase Chain Reaction; Rimonabant; RNA, Messenger; Tumor Necrosis Factor-alpha | 2009 |
Coordinated improvement in glucose tolerance, liver steatosis and obesity-associated inflammation by cannabinoid 1 receptor antagonism in fat Aussie mice.
Topics: Adipose Tissue; Animals; Diet, High-Fat; Disease Models, Animal; Fatty Liver; Glucose Intolerance; Glucose Tolerance Test; Inflammation; Insulin Resistance; Lipid Metabolism; Liver; Male; Mice; Obesity, Morbid; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2011 |
Induction of glucose intolerance by acute administration of rimonabant.
Topics: Administration, Oral; Animals; Benzoxazines; Blood Glucose; Dopamine Antagonists; Eating; Fenclonine; Glucose; Glucose Intolerance; Haloperidol; Hepatocytes; Infusions, Intraventricular; Insulin; Male; Mice; Morpholines; Naphthalenes; Ondansetron; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Receptors, Dopamine; Receptors, Serotonin; Rimonabant; Serotonin Antagonists | 2012 |
Targeted inactivation of GPR26 leads to hyperphagia and adiposity by activating AMPK in the hypothalamus.
Topics: Adiposity; AMP-Activated Protein Kinases; Animals; Diet; Dyslipidemias; Energy Metabolism; Enzyme Activation; Gene Silencing; Gene Targeting; Glucose Intolerance; Hyperinsulinism; Hyperphagia; Hypothalamus; Mice; Mice, Inbred C57BL; Obesity; Phosphorylation; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptors, G-Protein-Coupled; Rimonabant; Weight Loss | 2012 |
Metabolic risk factors, drugs, and obesity.
Topics: Anti-Obesity Agents; Cardiovascular Diseases; Dyslipidemias; Glucose Intolerance; Humans; Obesity; Overweight; Piperidines; Pyrazoles; Rimonabant; Weight Loss | 2006 |
The cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in Zucker rats.
Topics: Animals; Anti-Inflammatory Agents; Chemokine CCL2; Chemokine CCL5; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Glucose Intolerance; Inflammation Mediators; Leukocyte Count; Leukocytes; Lipids; Male; Metabolic Syndrome; Piperidines; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Pyrazoles; Rats; Rats, Zucker; Receptor, Cannabinoid, CB1; Rimonabant; Time Factors; Weight Gain | 2008 |